Quantcast

Latest epilepsy Stories

2014-07-23 12:32:42

LONDON, July 23, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Generalized Tonic-Clonic Seizure Global Clinical Trials Review, H2, 2014https://www.reportbuyer.com/product/2243627/Generalized-Tonic-Clonic-Seizure-Global-Clinical-Trials-Review-H2-2014.htmlGeneralized Tonic-Clonic Seizure Global Clinical Trials Review, H2, 2014SummaryGlobalData's clinical trial report, "Generalized Tonic-Clonic Seizure Global Clinical Trials Review, H2, 2014" provides data...

2014-07-23 12:31:49

LONDON, July 23, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Neurostimulation: Technologies and Global Marketshttps://www.reportbuyer.com/product/2070063/Neurostimulation-Technologies-and-Global-Markets.htmlREPORT HIGHLIGHTSThe global neurostimulation devices market is expected to reach $3.8 billion in 2013 and $4.1 billion in 2018, with a compound annual growth rate (CAGR) of 1.5%.This report provides:An overview of the global market for...

2014-07-23 08:31:01

- Brivaracetam is the newest investigational medicine to emerge from UCB's rich late-stage pipeline BRUSSELS, July 23, 2014 /PRNewswire/ -- regulated information -- UCB today announced an important advance in its research and development pipeline with positive topline results from the latest Phase 3 study with brivaracetam. This study was designed to evaluate the efficacy and safety of brivaracetam (100 and 200 mg/day, without titration) compared to placebo, as adjunctive treatment in adult...

2014-07-22 08:30:55

LOS ANGELES, July 22, 2014 /PRNewswire/ -- NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch(TM) eTNS(TM) Therapy for the treatment of neurological and neuropsychiatric disorders, today announced that enrollment has begun in a pediatric open label study of external trigeminal nerve stimulation (eTNS) as adjunctive therapy for the treatment of Lennox-Gastaut Syndrome (LGS). The trial is being conducted at...

2014-07-18 23:01:32

Transparency Market Research added a new report "Global Epilepsy Therapeutics Market: Industry Analysis, Size, Share, Growth and Forecast 2019" to its report store. Browse the full report: http://www.transparencymarketresearch.com/epilepsy-therapeutics-market.html. (PRWEB) July 18, 2014 Epilepsy is a group of long-term neurological disorders that is characterized by recurring seizures. These seizures are episodes that occur when group of nerve cells or neurons in brain sends...

2014-07-17 16:20:33

Attribute to Susan Axelrod, Founding Chair, Citizens United for Research in Epilepsy (CURE) CHICAGO, July 17, 2014 /PRNewswire-USNewswire/ -- "CURE applauds the announcement today from the U.S. Department of Defense - allocating $7.5 million dedicated to epilepsy research - and thanks Senator Dick Durbin (D-IL) for his leadership on this issue. The incidence of epilepsy increased by an alarming 52 percent from 2006 to 2010, with approximately 8 percent of those afflicted having been...

2014-07-16 20:23:07

LONDON, July 16, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability https://www.reportbuyer.com/product/2052296/Epilepsy-Therapeutics-in-Asia-Pacific-Markets-to-2019---Treatment-Options-Enhanced-As-Novel-Next-Generation-AEDs-Show-Improved-Safety-and-Tolerability.html Epilepsy Therapeutics in Asia Pacific...

2014-07-15 16:27:31

LONDON, July 15, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Epilepsy Therapeutics in Major Developed Markets to 2019 - New AEDs with Novel Mechanisms of Action Signal a Shift in Treatment Patternshttps://www.reportbuyer.com/product/2052297/Epilepsy-Therapeutics-in-Major-Developed-Markets-to-2019---New-AEDs-with-Novel-Mechanisms-of-Action-Signal-a-Shift-in-Treatment-Patterns.htmlEpilepsy Therapeutics in Major Developed Markets to 2019 - New AEDs with...

2014-07-15 08:28:37

WAYNE, Pa. and PORTO, Portugal, July 15, 2014 /PRNewswire/ -- BIAL, a research based international pharmaceutical company, and moksha8, a leading specialty pharmaceutical company in Latin America, announced today an exclusive license for the commercialization of eslicarbazepine acetate (Zebinix® / (Exalief®) in Brazil and Mexico for the treatment of epilepsy. Epilepsy is one of the most common neurological diseases, affecting 70 million worldwide and up to 5 million people in Latin America...

2014-07-14 08:27:51

Authorized Generic Topiramate Extended-Release Capsules Available Nationwide MAPLE GROVE, Minn., July 14, 2014 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. (Upsher-Smith), today announced the launch of Topiramate Extended-Release Capsules, the authorized generic of the recently Food and Drug Administration (FDA) approved Qudexy(TM) XR (topiramate) extended-release capsules, a once-daily, broad-spectrum antiepileptic drug specifically engineered to deliver a smooth pharmacokinetic (PK)...


Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related